What does this research mean for the field?

For belantamab to be cost-effective compared to daratumumab in treating relapsed or refractory multiple myeloma in China, its price must be set at US$5.73/mg, requiring an approximate 98% reduction from the US list price. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To estimate the value-based threshold price of belantamab plus bortezomib and dexamethasone compared with daratumumab plus bortezomib and dexamethasone for relapsed or refractory multiple myeloma.

September 14, 2026PharmacoEconomics - OpenOpen Access

Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis

View Full Paper

Ask AI

Bookmark

Authors

XZXiaotong Zhang XXXiaoxuan Xing ZWZhizhou Wang

Discussion

Member takes

Overview

Randomized trial evaluation reveals a threshold price of US$5.73/mg for belantamab in relapsed or refractory multiple myeloma, indicating a ninety-eight percent price reduction is required.

Key Points

To estimate the value-based threshold price of belantamab plus bortezomib and dexamethasone compared with daratumumab plus bortezomib and dexamethasone for relapsed or refractory multiple myeloma.
Constructed a three-state partitioned survival model over a lifetime horizon utilizing clinical efficacy data from the DREAMM-7 interventional trial (NCT04246047).
Incorporated drug acquisition and administration, subsequent treatments, disease monitoring, and adverse event costs alongside published health utility values, discounted at 4.5% annually.
Conducted probabilistic sensitivity analysis using 10,000 Monte Carlo simulations at a willingness-to-pay threshold of twice the projected 2025 GDP per capita (US$29,444 per quality-adjusted life year).
Belantamab plus bortezomib and dexamethasone (BVd) generated 6.15 QALYs compared with 4.51 QALYs for daratumumab plus bortezomib and dexamethasone (DVd).
The probabilistic mean threshold price for belantamab was US$5.73/mg (95% CrI 2.16–8.89) at the US$29,444/QALY willingness-to-pay threshold.
Achieving cost-effectiveness at the specified threshold requires an approximate 98% price reduction relative to the United States list price.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3580926e14a848b223a https://doi.org/10.1007/s41669-026-00681-8

View Full Paper

Ask AI

Bookmark

September 14, 2026PharmacoEconomics - OpenOpen Access

Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis

View Full Paper

Ask AI

Bookmark

Authors

XZXiaotong Zhang XXXiaoxuan Xing ZWZhizhou Wang

Discussion

Member takes

Overview

Randomized trial evaluation reveals a threshold price of US$5.73/mg for belantamab in relapsed or refractory multiple myeloma, indicating a ninety-eight percent price reduction is required.

Key Points

To estimate the value-based threshold price of belantamab plus bortezomib and dexamethasone compared with daratumumab plus bortezomib and dexamethasone for relapsed or refractory multiple myeloma.
Constructed a three-state partitioned survival model over a lifetime horizon utilizing clinical efficacy data from the DREAMM-7 interventional trial (NCT04246047).
Incorporated drug acquisition and administration, subsequent treatments, disease monitoring, and adverse event costs alongside published health utility values, discounted at 4.5% annually.
Conducted probabilistic sensitivity analysis using 10,000 Monte Carlo simulations at a willingness-to-pay threshold of twice the projected 2025 GDP per capita (US$29,444 per quality-adjusted life year).
Belantamab plus bortezomib and dexamethasone (BVd) generated 6.15 QALYs compared with 4.51 QALYs for daratumumab plus bortezomib and dexamethasone (DVd).
The probabilistic mean threshold price for belantamab was US$5.73/mg (95% CrI 2.16–8.89) at the US$29,444/QALY willingness-to-pay threshold.
Achieving cost-effectiveness at the specified threshold requires an approximate 98% price reduction relative to the United States list price.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3580926e14a848b223a https://doi.org/10.1007/s41669-026-00681-8

View Full Paper

Ask AI

Bookmark